LEAP THERAPEUTICS, INC. Quarterly Debt-to-equity in % from Q3 2018 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Leap Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2018 to Q2 2024.
  • Leap Therapeutics, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 20.4 %, a 7.1% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 20.4 +1.35 +7.1% Jun 30, 2024
Q1 2024 17.5 -1.2 -6.42% Mar 31, 2024
Q4 2023 18.8 +5.37 +39.9% Dec 31, 2023
Q3 2023 18.4 +7.22 +64.4% Sep 30, 2023
Q2 2023 19 +9.29 +95.6% Jun 30, 2023
Q1 2023 18.7 +8.3 +79.9% Mar 31, 2023
Q4 2022 13.5 +0.9 +7.17% Dec 31, 2022
Q3 2022 11.2 -3.66 -24.6% Sep 30, 2022
Q2 2022 9.72 -8.5 -46.7% Jun 30, 2022
Q1 2022 10.4 -5.02 -32.6% Mar 31, 2022
Q4 2021 12.6 -6.52 -34.2% Dec 31, 2021
Q3 2021 14.9 -12.5 -45.6% Sep 30, 2021
Q2 2021 18.2 -26.6 -59.3% Jun 30, 2021
Q1 2021 15.4 -100 -86.6% Mar 31, 2021
Q4 2020 19.1 -94.1 -83.1% Dec 31, 2020
Q3 2020 27.4 -58.5 -68.1% Sep 30, 2020
Q2 2020 44.8 -66.2 -59.7% Jun 30, 2020
Q1 2020 115 -21.7 -15.8% Mar 31, 2020
Q4 2019 113 -57.6 -33.7% Dec 31, 2019
Q3 2019 85.9 -95.1 -52.6% Sep 30, 2019
Q2 2019 111 Jun 30, 2019
Q1 2019 137 Mar 31, 2019
Q4 2018 171 Dec 31, 2018
Q3 2018 181 Sep 30, 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.